E-cadherin is a key cell adhesion molecule implicated as a tumor suppressor, which is frequently altered in hepatocellular carcinoma, especially in hepatitis B virus (HBV)-related tumors. Here, we report that HBV X protein (HBx) represses E-cadherin expression at the transcription level. Based on the differential effects of HBx natural variants, we determined that Lys-130 in the transactivation domain of HBx is critical for the E-cadherin repression. The repression effect of HBx was abolished after treatment with DNA methyltransferase inhibitor, 5 0 -Aza-2 0 dC. In addition, methylation-specific PCR analysis revealed that the CpG island 1 of E-cadherin promoter is hypermethylated by HBx. Furthermore, HBx induces DNA methyltransferase 1 expression by stimulating its transcription. Therefore, we conclude that HBx represses E-cadherin expression by inducing methylation-mediated promoter inactivation. The reduced E-cadherin expression results in dramatic morphological changes of the HBxexpressing cells. In addition, HBx-expressing cells aggregate poorly in suspension culture, reflecting their altered intercellular interactions. The biological significance was further demonstrated by the increased collagen invasion ability of HBx-expressing cells. Therefore, the present study suggests that HBx plays a role during hepatocellular carcinogenesis by favoring cell detachment from the surrounding cells and migration outside of the primary tumor site.
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Introduction
Hepatitis B virus (HBV) is strongly associated with the development of hepatocellular carcinoma (HCC) (Block et al., 2003; Anzola, 2004) . One of the open-reading frames encoded by the HBV genome is an oncogenic X protein (HBx), which is the most frequently integrated viral sequence found in HCCs. HBx is likely to be implicated in the several different steps of carcinoma development. Most efforts in the study of the role of HBx in HCC development have focused on its involvement in the genesis of liver carcinomas. In this regard, HBx is able to induce HCC either alone or in synergy with c-Myc or chemical carcinogens in transgenic mice (Kim et al., 1991; Terradillos et al., 1997) . HBx activates several signal transduction pathways that lead to the transcriptional upregulation of a number of cellular genes, including those of growth factors and oncogenes (Feitelson and Duan, 1997; Diao et al., 2001 ). In addition, HBx promotes cell cycle progression, inactivates negative growth regulators like p53 (Wang et al., 1994) and facilitates the accumulation of DNA mutations by interfering with the DNA repair machinery (Jia et al., 1999) . HBx is also able to interfere with apoptotic signals, leading to tumor cell survival, although this issue remains controversial (Wang et al., 1995; Shih et al., 2000) .
Recently, several reports have demonstrated that HBx is also implicated in the late stages of tumor progression, metastasis and angiogenesis. HBx induces extensive morphological changes and cytoskeleton rearrangements in liver cells (Lara-Pezzi et al., 2001c) . It induces adherens junction disruption (Lara-Pezzi et al., 2001b) and modulates integrin-mediated adhesion to extracellular matrix (ECM) (Lara-Pezzi et al., 2001a) . In addition, HBx promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase 1 (MT1-MMP) (Lara-Pezzi et al., 2002) , MMP-9 (Chung et al., 2004) and urokinase-type plasminogen activator (Chan et al., 2004) . Also, HBx activates hypoxia-inducible factor-1a, which promotes angiogenesis through activation of several angiogenic factors like vascular endothelial growth factor (Yoo et al., 2003) . However, the role of HBx in tumor invasion and metastasis and the underlying mechanisms are far from being fully understood.
The cell-cell adhesion molecule E-cadherin has been shown to execute important functions in embryogenesis and tissue architecture by forming intercellular junction complexes and establishing cell polarization (Wheelock and Johnson, 2003) . The extracellular domain of E-cadherin is involved in a molecular zipper mediating cell-cell adhesion, whereas the cytoplasmic tail is linked to the actin cytoskeleton via catenins. Owing to its critical function in intercellular adhesion, E-cadherin has been assumed to act as a tumor suppressor negatively regulating several critical steps of invasion and metastasis (Hirohashi, 1998; Hirohashi and Kanai, 2003) . Immunohistochemical studies of E-cadherin expression in HBV-related HCC demonstrated significant downregulation of E-cadherin in the tumor tissue compared with adjacent nontumor tissues (Yoshiura et al., 1995; Kanai et al., 1997) . However, the underlying mechanism for the E-cadherin repression in HBVinduced HCC is still unknown. In this study, we demonstrate that HBx induces DNA methyltransferase 1 (DNMT1) expression and activity, which in turn results in hypermethylation/inactivation of the E-cadherin promoter and subsequently repression of the E-cadherin expression. In addition, we provide evidence for the functional relevance of this phenomenon by demonstrating that downregulation of E-cadherin leads to morphological changes and altered cell-to-cell interactions and in parallel to an invasive growth behavior.
Results

HBx represses E-cadherin gene expression
The downregulation of E-cadherin is implicated in the malignant progression of HCCs, especially in HBVrelated tumors (Matsumura et al., 2001; Wei et al., 2002) . However, the viral factor responsible for this phenomenon is unknown. Therefore, we first investigated whether HBx represses E-cadherin expression in cultured human liver cells. For this purpose, we transiently transfected HBx-expressing plasmid, pCMV-3 Â hemagglutinin (HA)-HBX3 (HBX3) (Kwun and Jang, 2004) , into a human hepatoma cell line HepG2. As a result, the E-cadherin protein level was reduced by HBx in a dose-dependent manner (Figure 1a ). The level of E-cadherin mRNA in HepG2 cells, as determined by semiquantitative RT-PCR, was similarly decreased by HBx (Figure 1b) , which suggests that HBx represses E-cadherin expression at the transcription level. Furthermore, to investigate the effect of HBx on the E-cadherin promoter activity, we performed luciferase assay, using the E-cadherin-luciferase reporter (Ecad À420/ þ 32 ) that contains luciferase gene under the control of full-length E-cadherin promoter. As a result, we found that HBx specifically represses the E-cadherin promoter activity in a dose-dependent manner, up to approx. fourfold ( Figure 1c) . Therefore, we conclude that HBx represses E-cadherin expression at the transcription initiation step by modulating its promoter activity.
Lys-130 residue in HBx is critical for the downregulation of E-cadherin expression
We next tried to determine the region of HBx responsible for the repression of E-cadherin. For this purpose, we first compared the repression ability of two natural variants, HBX3 and hbx2 (Kwun and Jang, 2004). HBX3, employed throughout this study, is derived from a patient with HCC, whereas hbx2 from a mild hepatitis patient. According to our previous report (Kwun and Jang, 2004 ), these two variants have different effects on the p21 expression and subsequently on the cell growth control. According to Figure 2a and b, the two variants produced completely different effects on the E-cadherin expression. As the repression effect was observed with HBX3 but not with hbx2, we hypothesized that the unique amino-acid residues in HBX3 are critical for the effect. Among the six aminoacid residues that are different between HBX3 and hbx2 (Figure 2a) , the double substitution S101P and K130M was critical for the differential regulation of p21 expression (Kwun and Jang, 2004) . Therefore, we investigated whether these two amino-acid residues are also responsible for the different effects on the E-cadherin expression. For this purpose, we employed three artificial hbx2 mutants, each of which contains a . Therefore, we conclude that Lys-130 is critical for the repression of E-cadherin.
HBx represses E-cadherin expression by inducing hypermethylation of E-cadherin promoter
It has been suggested that hypermethylation of the E-cadherin promoter is frequently associated with the downregulation of E-cadherin expression in HBVrelated tumors (Nabi, 1999; Melki et al., 2000) . Therefore, we tested the possibility of E-cadherin promoter inactivation via HBx-induced hypermethylation. For this purpose, we established five stable HepG2 cell lines with HBX3-expressing vector and three lines with empty vector. Figure 3 shows the results obtained from the representatives of each transfection. The expression of HBx in the stable cell lines was confirmed by Western blotting (Figure 3a) . Consistently with the transient transfection experiment, E-cadherin expression was significantly repressed in HBx-expressing cell lines ( Figure 3a) . Interestingly, the expression of E-cadherin in HBx-expressing cells was completely restored after treatment with DNMT inhibitor, 5 0 -Aza-2 0 dC. In addition, the reduced E-cadherin promoter activity by HBx was also restored after treatment with 5 0 -Aza-2 0 dC for 24 h ( Figure 3b ).
Next, we investigated whether HBx actually induces hypermethylation of the E-cadherin promoter. Genomic DNA extracted from the stable cell lines was treated with sodium bisulfite, converting deoxycytosine but not 5-methylcytosine residues into uracil through deamination. When methylation-specific PCR (MSP) for the amplification of methylated CpG island 1 (nt À177 to À63) was performed, significantly higher frequencies of 5-methylcytosine residues were detected in HBx-expres- Each HBx-expressing construct (5 mg) was cotransfected with Ecad À420/ þ 32 and luciferase assay was performed as described in Figure 1c . Repression fold was calculated by dividing the luciferase activity of HBx-expressing cells by the basal activity of the control.
(b) Western blotting of E-cadherin in HepG2 cells transiently transfected with HBx construct (5 mg) was performed as described in Figure 1a results in promoter inactivation and subsequently reduced expression of E-cadherin.
HBx activates DNMT1
HBx may induce hypermethylation of E-cadherin promoter by enhancing cellular DNMT activity. When DMMT activity was compared between the two cell lines, it was about fivefold higher in HBx-expressing cells (Figure 4a ). We next tried to investigate whether the increase of DNMT activity in HBx-expressing cells is due to the enhanced expression of DNMT1. Both RNA and protein levels of DNMT1 were significantly increased in the HBx-expressing cells (Figure 4b and c, respectively), which suggests that HBx induces the expression of DNMT1 by stimulating its transcription. A similar effect of HBx on the expression of DNMT1 was observed with transient transfection experiments (Figure 4b and c), indicating that activation of DNMT1 reflects a real effect of HBx rather than a clonal variation. Treatment with 5 0 -Aza-2 0 dC did not affect the RNA level of DNMT1, but significantly decreased its protein level (Figure 4b and c), suggesting that 5 0 -Aza-2 0 dC restores expression of E-cadherin in the presence of HBx as shown in Figure 3 through sequestration of the DNMT1 to azacytosine residues in DNA, resulting in genome-wide demethylation (Santi et al., 1984) .
To provide a more direct evidence for the role of DNMT1 in the regulation of E-cadherin gene by HBx, we attempted to knock down DNMT1 expression by introducing a specific siRNA into HBx-expressing cells. As expected, DNMT1 expression was specifically decreased by DNMT1 siRNA in a dose-dependent manner (Figure 4d) . Accordingly, E-cadherin expression was increased, proving that DNMT1 plays a direct role in the repression of E-cadherin by HBx. E-cadherin repression by HBx modulates intercellular interaction and invasion ability E-cadherin is a cell surface molecule that plays a major role in cell-cell adhesive interactions, together with ECM contacts (Wheelock and Johnson, 2003) . Therefore, the reduced E-cadherin in HBx-expressing cells may alter cell-to-cell interactions. Both the parental HepG2 (data not shown) and the vector-transfected cells ( Figure 5a) were tightly connected to each other, forming cell clusters. However, the HBx-expressing cells did not form such tight intercellular connections, but loosely connected to each other. In addition, HBx-expressing cells were often spindle shaped with 4) for 24 h. Western blotting was performed as described in Figure 1a. (b) HepG2-vector and HepG2-HBX3 cells were transfected with Ecad À420/ þ 32 in the presence or absence of 5 0 -Aza-2 0 dC and luciferase assay was performed as described in Figure 2a . (c) Genomic DNA was purified from HepG2-vector (lanes 1 and 3) and HepG2-HBX3 cells (lanes 2 and 4) after either mock treated (lanes 1 and 2) or treated with 5 mM 5 0 -Aza-2 0 dC (lanes 3 and 4) for 24 h. MSP analysis was performed to determine whether CpG island 1 within the E-cadherin promoter is either methylated (M) or unmethylated (U). Each band was quantified suing BIO-PROFIL Bio-1D image analysis software (Vilber Lourmat, France). Methylation index (M/U) was prepared to compare the methylation status of E-cadherin promoter among samples. (d) HepG2 cells were transfected with Ecad À420/ þ 32 in the presence or absence of HBx and were either mock treated (lanes 1 and 2) or treated with 5 mM 5 0 -Aza-2 0 dC (lanes 3 and 4) for 24 h. After modification of the purified DNA, a 460-bp fragment containing parts of E-cadherin promoter and luciferase gene was amplified for the detection of either unmethylated (U) or methylated templates (M) elongated protrusions, which probably reflects the altered structure of cytoskeletons (Figure 5a ). Both the morphological changes and altered cell-cell interactions induced by HBx must be attributable to the reduced E-cadherin expression because both alterations were Fast aggregation assay of HepG2-vector and HepG2-HBX3 cell lines were performed as described previously (Kawanishi et al., 1995) . Cells were treated with 5 mM 5 0 -Aza-2 0 dC for 24 h or left untreated before subjection to aggregation assay for the indicated time. (c) Collagen type I invasion assay of HepG2-vector and HepG2-HBX3 cells. Cells (1 Â 10 6 ) were applied to the upper chamber of the device with polycarbonate membrane coated with 1 mg/ml collagen type I. As a control, a parallel experiment was performed using the device with uncoated membrane. The experiment was repeated three times prepared with duplicate almost completely restored after treatment with 5 0 -Aza-2 0 dC for 24 h. To evaluate the effect of HBx on the cell-to-cell interactions, we measured cell aggregation ability of the stable cell lines. Cells were dissociated by trypsin treatment to monocellular suspensions and allowed to aggregate in suspension culture. Contrary to the control cells, HBx-expressing cells aggregated poorly in suspension culture (Figure 5b ). In addition, the aggregation ability of HBx-transfected cells was completely restored to the level of control cells after treatment with 5 0 -Aza-2 0 dC, which confirms that the reduced E-cadherin expression by HBx leads to the decreased cell-to-cell interactions.
It has been described that reduced E-cadherin expression is strongly correlated with enhanced cell invasiveness in vitro and tumor progression in vivo (Hirohashi and Kanai, 2003; Foty and Steinberg, 2004) . Therefore, we finally examined whether the reduced E-cadherin by HBx affects cell invasiveness in vitro. Each cell line was either left untreated or treated with 5 0 -Aza-2 0 dC for 24 h and subjected to the transwell migration assay. The HBx-expressing cells showed approximately twofold higher % invasion, which was reverted to the control level after treatment with 5 0 -Aza-2 0 dC (Figure 5c ). Therefore, we conclude that HBx-mediated E-cadherin repression also increases cell invasion ability.
Discussion
Several recent studies provided consistent evidence for a role of E-cadherin as a potent tumor suppressor (Hirohashi and Kanai, 2003) . Transfection of Ecadherin cDNA into invasive carcinoma cells led to significant reduction of their invasive capacity in vitro (Frixen et al., 1991) , and activation of E-cadherin resulted in growth retardation of tumor cell lines (Watabe et al., 1994) . In addition, loss or alteration of E-cadherin expression during tumor development was observed in a variety of different tumor types, including HCC (Berx et al., 1996; Silye et al., 1998; Sanders et al., 1999; Melki et al., 2000) . Therefore, knowledge of the molecular mechanism that represses its expression or function is of primary importance in understanding the process of tumor invasion. Here, we further demonstrate that the major HBV oncoprotein, HBx, induces hypermethylation of the E-cadherin promoter, which results in the repression of E-cadherin expression and subsequently alteration of morphological properties and cell migration ability. It is also possible to speculate that HBx represses E-cadherin expression by elevating the activity of transcriptional repressors such as Snail-and Smad-interacting protein 1 (Cano et al., 2000) , although it has not yet been demonstrated in the clinical samples. However, according to the present study, the altered expression of E-cadherin in the presence of HBx could be completely restored by treatment with DNMT inhibitor 5 0 -Aza-2 0 dC. In addition, the mutated E-cadherin promoter, in which both E-Boxes are destructed by point mutations, showed almost the same response to HBx with the wild-type promoter (data not shown). Therefore, the possibility that HBx represses Ecadherin by upregulating negative regulators can be excluded. The underlying mechanism by which HBx activates DNMT1 expression is still unknown. HBx is known to activate AP-1 transcriptional activity through several intracellular signal transducers such as extracellular signal-regulated kinase 1/2 (Chung et al., 2004) and c-Jun N-terminal kinases (Benn et al., 1996) . Therefore, it is possible to speculate that HBx may activate the DNMT1 gene via upregulation of AP-1 activity since DNMT1 promoter contains the binding motifs of the AP-1 complex (Bigey et al., 2000) .
During a long period of HBV replication in the liver of patients, several mutations can be accumulated in the HBx coding region, which can affect its oncogenic potential. Interestingly, some point mutations in HBx gene, in particular, the double substitution K130M and V131I, are more frequent in the sera of patients with cirrhosis and/or HCC than in patients with mild liver disease (Hsia et al., 1996; Takahashi et al., 1998; Baptista et al., 1999; Venard et al., 2000) . According to the present study, only the HBx containing Lys-130 instead of Met-130 effectively represses E-cadherin. It is difficult to explain why the single substitution generates such a dramatic difference in the potential for Ecadherin regulation. Interestingly, Lys-130 is located in the transactivation domain of HBx (Diao et al., 2001 ). Thus, it is possible to speculate that Lys-130-containing HBx may activate DMMT1 expression more strongly, which effectively results in E-cadherin promoter methylation/inactivation. Another problem is to explain that the Met-130-containing HBx, which is more frequently detected in the sera of patients with HCC, is inactive for the repression of E-cadherin. Actually, the Lys-130-containing HBx (HBX3) was isolated from the sera of patient with HCC, whereas the Met-containing one (hbx2) from a hepatitis patient (Kwun and Jang, 2004) . Therefore, to evaluate properly the importance of the substitution for the E-cadherin repression, more extensive studies should be performed. In addition, it is intriguing to investigate whether the K130M substitution also affects other regulatory activities of HBx.
The deadhesion of tumor cells from the primary tumor site is the first step in metastasis, and often requires downregulation of adhesion molecules (Miyasaka, 1995) . In this study, we observed that the reduced E-cadherin expression results in dramatic morphological changes, often to spindle shape with elongated protrusions. This kind of alteration is closely associated with migration of adherent cells (Nabi, 1999; Lara-Pezzi et al., 2001a) . In addition, HBx-expressing cells aggregate poorly in suspension culture, reflecting their altered intercellular interactions. The biological significance was further demonstrated by the increased collagen invasion ability of HBx-expressing cells. Therefore, the present study suggests that HBx plays a role during hepatocellular carcinogenesis by favoring cell detachment from the surrounding matrix and migration outside of the primary tumor site.
Materials and methods
Plasmid construction
The full-length E-cadherin promoter (GenBank Accession No. AY341818) was obtained from genomic DNA of HepG2 cells by PCR amplification using a primer set, Ecad À420 forward (5 0 -ACC GCT CGA GCC CAG GAG TT-3 0 , À420 to À401) and Ecad þ 32 reverse (5 0 -CCG CAA GCT TAC AGG TGG T-3 0 , þ 37 to þ 19). The PCR product was subcloned into the XhoI and HindIII sites of the luciferase reporter vector, pGL2-basic (Promega), to create Ecad À420/ þ 32 . HBx-expressing plasmids, pCMV-3 Â HA1-HBX3, -hbx2, -hbx2P101S, -hbx2M130K and -hbx2P101S/M130K, encode the corresponding full-length HBx sequence (nt 1374-1838) downstream of three copies of the influenza virus HA epitope (a nonapeptide sequence (YPYDVPDYA)) as described previously (Lee et al., 1998) .
Cell culture
HepG2 (KCLB No. 58065) was obtained from the Korean Cell Line Bank. Stable cell lines were established by transfection with either an empty vector pCMV-3 Â HA1 (Lee et al., 1998) or pCMV-3 Â HA1-HBX3 (Kwun and Jang, 2004), followed by selection with 500 mg/ml G418 (Gibco). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum.
Transfection and luciferase assay
HepG2 cells were seeded at 2 Â 10 5 cells/60 mm diameter plate and transfected the next day either using the Fugenet 6 transfection kit (Roche) or with a calcium phosphate-DNA precipitation method as described previously (Gorman et al., 1982) . To control for the variation in transfection efficiency, 0.1 mg pCH110 (Pharmacia) containing the Escherichia coli lacZ gene under the control of the SV40 promoter was cotransfected as an internal control. At 48 h after transfection, the level of expression from the luciferase activity was analysed and the value obtained was normalized to the b-galactosidase activity measured in the corresponding cell extract. Each experiment was repeated at least three times prepared in triplicate.
Transfection of siRNA
Both DNMT-1 (sc-35204) and control (sc-37007) siRNAs were purchased from Santa Cruz Biotechnology. Cells were transfected with 100 nM of siRNA using Oligofectamine transfection reagent (Invitrogen) in Opti-MEM I reduced serum medium (Invitrogen) for 6 h. The medium was removed and replaced with fresh DMEM supplemented with 10% fetal calf serum. Cells were harvested 72 h after transfection for Western blotting analysis.
Semiquantitative RT-PCR
For RT-PCR, total cellular RNA was extracted from HepG2 cells using Trizol (Gibco). DNase I-digested RNA (3 mg) was reverse transcribed with the corresponding antisense primer. One-quarter of the reverse-transcribed RNA was amplified with Taq polymerase (951C for 5 min; 30 cycles of 951C for 1 min, 561C for 1 min; 721C for 30 s, 721C for 5 min) using the sense primers, 5 0 -GGT TAT TCC TCC CAT CAG CT-3 0 , 5 0 -CCG AGT GCG TCC AGG TGT ACT CCA T-3 0 , 5 0 -ACC GAA TTC CCA TGG CTG CT-3 0 and 5 0 -ACC ACA GTC CAT GCC ATC AC-3 0 ; and antisense primers, 5 0 -CTT GGC TGA GGA TGG TGT A-3 0 , 5 0 -GTT GCA GTC CTC TGT GAA CAC TGT GG-3 0 , 5 0 -AAC TCT AGA TGA TTA GGC AGA GGT-3 0 and 5 0 -TAC AGC AAC AGG GTG GTG GA-3 0 for E-cadherin, DNMT1, HBx and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), respectively.
Western blotting analysis
Cells were lysed in buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40) supplemented with protease inhibitors. Protein concentration of cell extracts was measured using the bovine serum albumin protein assay kit (Bio-Rad). In all, 20 mg of cell extracts were separated by SDS-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (Hybond PVDF, Amersham). Western blotting was performed with mouse monoclonal anti-human E-cadherin antibody (Calbiochem), goat polyclonal anti-DNMT1 antibody (Santa Cruz), mouse monoclonal anti-HA antibody (Roche) for HBx, mouse monoclonal anti-actin antibody (Santa Cruz) and subsequently detected by chemiluminescent ECL kit (Amersham) as recommended by the manufacturer.
Cell aggregation assay
Fast aggregation assay was performed as described previously (Kawanishi et al., 1995) . Cells were dissociated with Hank's balanced salt solution (HBSS) with 0.01% trypsin and 1 mM CaCl 2 and washed twice in Ca 2 þ -free HBSS. The resulting cells (1 Â 10 5 ) resuspended in 2 ml of HBSS containing 1 mM CaCl 2 were incubated for the indicated time at 371C on a gyratory shaker. After incubation, the total particle number (single cells plus cell clusters) in each cell suspension was counted. The degree of aggregation was represented by the aggregation index N t /N 0 , where N 0 was the total particle number before incubation and N t was the total particle number after incubation for t minutes (Kawanishi et al., 1995) .
Methylation-specific PCR
Genomic DNA (1 mg) denatured in 50 ml of 0.2 N NaOH was modified by treatment with 30 ml of 10mM hydroquinone (Sigma) and 520 ml of 3 M sodium bisulfite (Sigma), pH 5.0, at 501C for 16 h. The modified DNA (100 ng) was amplified with Taq polymerase using the appropriate primer pairs under the conditions described previously (Herman et al., 1996) . MSP primers for methylated E-cadherin promoter were M1 (5 0 -TTA GGT TAG AGG GTT ATC GCG T-3 0 ) and M2 (5 0 -TAA CTA AAA ATT CAC CTA CCG AC-3 0 ) (Herman et al., 1996) . For unmethylated DNA amplification, U1 (5 0 -TAA TTT TAG GTT AGA GGG TTA TTG T-3 0 ) and U2 (5 0 -CAC AAC CAA TCA ACA ACA CA-3 0 ) were used (Herman et al., 1996) . For MSP analysis of the transfected E-cadherin promoter, total DNA was purified from HepG2 cells transfected with Ecad À420/ þ 32 . To exclude the amplification of endogenous E-cadherin promoter, a fragment from Ecadherin promoter to luciferase open-reading frame in Ecad À420/ þ 32 was amplified using M1 and M3 (Luci þ 240 ) (5 0 -TTC CGC GTA CGT AAT ATT CA-3 0 ) for the methylated template. For the amplification of unmethylated templates, U1 and U3 (Luci þ 240 ) (5 0 -TTC CAC ATA CAT AAT ATT CA-3 0 ) were employed.
DNMT activity assay
DNMT activity was determined as described previously (Rhee et al., 2000) . Briefly, the cell lysate was incubated with 0.5 mg poly-d(IÀC) and 5 mCi adenosyl-methionine S-[methyl-H 3 ] (Amersham) to a final volume of 15 ml at 371C for 2 h. The reaction was terminated with 40 ml of stop solution (1% SDS, 2 mM EDTA, 5% butanol, 125 mM NaCl, 250 mg/ml salmon sperm DNA). The reaction product was precipitated with ethanol, and resuspended in 30 ml of 0.3 M NaOH. The solution was spotted on GF/C filter disk (Whatman), washed with 5% trichloroacetic acid and evaluated in a scintillation counter.
Transwell cell migration assay
Cell migration ability was evaluated by using the chemotaxis chamber (Corning costar) as described previously (Tsai et al., 2002) . Polycarbonate membrane with a pore size of 8 mm was coated with medium containing 1 mg/ml collagen type I (Sigma). Cells (1 Â 10 6 ) in 1.5 ml of culture medium were applied to the upper chamber of the device, and 2.6 ml of medium were added to the lower chamber. As a control, a parallel experiment was performed using the device with uncoated membrane. After 24 h of incubation at 371C, the membrane was fixed in methanol for 10 min and stained with Giemsa solution for 1 h. Migrated cells on the membrane were counted under a microscope. The results are expressed as follows: % invasion index ¼ (the number of cells migrating through the collagen-coated membrane/the number of cells migrating through the uncoated control membrane) Â 100.
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